DNA Damage and Oxidative Stress in Hospitalized COVID-19 Patients

University of Vienna135 enrolled

Overview

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus disease 2019 (COVID-19) pandemic challenging health systems worldwide. While there is a clear correlation between oxidative stress markers and the severity of many viral diseases such as hepatitis C, for SARS-CoV clinical data is limited. The investigators aim at 1.) investigating DNA damage, oxidative stress, inflammation, and aging markers in COVID-19 patients and compare them with age and gender matched healthy controls and patients with influenza; and 2.) investigating all aforementioned parameters during "cytokine storm" via repeated blood sampling.

Study Type

OBSERVATIONAL

Enrollment

135

Conditions

Covid19

Interventions

No interventionOTHER

Case-control design, one single investigation

Eligibility

Sex: ALLMin age: 40 YearsHealthy volunteers:

Medical Language ↔ Plain English

Covid 19 group: Inclusion Criteria: * gender: female/male * age: ≥40 years * patients admitted at the emergency department * COVID-19 suspected patients * able to give written informed consent Exclusion Criteria: * children (≤ 18 years) and adults 19-39 years * not hospitalized, but confirmed COVID-19 patients (outpatients) * patients without definitive COVID-19 confirmation Control group: Inclusion criteria: * gender: female/male * age: ≥40 years * absence of severe illnesses/serious diseases * able to give written informed consent Exclusion criteria: * children (≤ 18 years) and adults 19-39years * any current or past clinically significant pathology/disease (comorbidity) such as: * Malignancies * Cardiovascular diseases * Diabetes mellitus (I and II) * Obesity class III (BMI \>40) * Other severe diseases (e.g. renal, hepatic, thyroid disease, bone metabolic diseases, rheumatoid osteoarthritis, human immunodeficiency syndrome, …) Influenza group: Inclusion criteria: * gender: female/male * age: ≥40 years * patients admitted at the emergency department * influenza suspected patients * able to give written informed consent Exclusion criteria: * children (≤ 18 years) and adults 19-39 years * patients without definitive influenza confirmation

Outcomes

Primary Outcomes

DNA damage

Compare DNA damage (% of DNA in the tail; measured by the comet assay) between hospitalized COVID-19 patients to influenza patients and healthy controls.

Time frame: Baseline

Secondary Outcomes

The investigators will consider further DNA damage parameter

Compare other DNA damage endpoints measured with the comet assay (i.e. tail length, tail moment and damage index) between hospitalized COVID-19 patients to influenza patients and healthy controls.

Time frame: Baseline

The investigators will consider oxidative stress marker

Compare oxidative stress biomarker malondialdehyde, FRAP, GSH, GSSG (all µmol/L) and the ration GSH/GSSG between hospitalized COVID-19 patients to influenza patients and healthy controls.

Time frame: Baseline

The investigators will consider inflammatory marker

Compare inflammatory marker Interleukin 1 (IL-1), IL-6, IL-8, IL-10, TNF-alpha (all rfU) and CRP (mg/dl) between hospitalized COVID-19 patients to influenza patients and healthy controls.

Time frame: Baseline

The investigators will consider the phenotypic age marker

Compare the phenotypic age marker between hospitalized COVID-19 patients to influenza patients and healthy controls.

Time frame: Baseline

The investigators will consider RDA and DNA gene expression

Compare RNA and DNA gene expression between hospitalized COVID-19 patients to influenza patients and healthy controls.

Time frame: Baseline

The investigators will consider clinical biochemistry marker

Compare clinical biochemistry (Total cholesterol (mg/dl), LDL-cholesterol (mg/dl), triglycerides (mg/dl), blood glucose (mg/dl), uric acid (mg/dl)) between hospitalized COVID-19 patients to influenza patients and healthy controls.

Time frame: Baseline

DNA Damage and Oxidative Stress in Hospitalized COVID-19 Patients

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes

Central Contacts